Healthcare startup exit strategies have become increasingly complex as biotechnology innovation intersects with evolving regulatory frameworks, reimbursement models, and capital market expectations. Founders and investors must now align scientific milestones with commercialization readiness and regulatory positioning to achieve optimal exit outcomes. In the United States, where oversight from the FDA, CMS, and SEC shapes market … Read more
Medical innovation continues to reshape the US healthcare landscape, but its trajectory is increasingly intertwined with capital market dynamics. Breakthroughs in biotechnology, digital therapeutics, and precision medicine are no longer evaluated solely on scientific merit. Investors, regulators, and healthcare stakeholders now assess innovation through the lens of scalability, reimbursement viability, and long-term return on investment. … Read more
Private funding vs public funding in biotech represents a foundational strategic decision that shapes a company’s trajectory, governance structure, and commercialization timelines. In the US biotechnology sector, where capital intensity and regulatory complexity are high, funding choices influence not only financial flexibility but also operational control and long-term value creation. Biotech companies typically navigate multiple … Read more